7,622.92

+42.85

+0.57%

52,324.53

+554.22

+1.07%

25,600.19

+163.19

+0.64%

2,837.69

+25.85

+0.92%

4.8800

-0.0490

-0.99%

19.10

-0.32

-1.65%

3,978.30

+79.40

+2.04%

77,340.33

-513.66

-0.66%

Crude Oil Dec 26

96.51

-7.61

-7.31%

US Private Equity

10,850.63

-82.20

-0.75%

XETRA - Delayed Quote EUR

BioNTech SE (22UA.DE)

78.15 -0.80 (-1.01%)

At close: 5:23:12 PM GMT+1

Loading Chart for 22UA.DE

Chart Range Bar

Interval:

In partnership with ChartIQ

BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook

BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook

BioNTech (BNTX) Phase 3 Breast Cancer Win Comes With A Lung Safety Warning

BioNTech (BNTX) Phase 3 Breast Cancer Win Comes With A Lung Safety Warning

Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher

Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher

Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?

Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?

The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings

The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings

Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady

Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?

BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?

BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach

BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

Moderna’s Cancer-Vaccine Leak Spurs Panic Selling. Wall Street Wanted a Cure.

Moderna’s Cancer-Vaccine Leak Spurs Panic Selling. Wall Street Wanted a Cure.

Mobilize your Website

View Site in Mobile | Classic

Share by: